FINHUB Insights

ABT · Q2 FY25 · Apr 1 – Jun 30, 2025

Abbott Laboratories Q2 FY25: where the revenue came from and where it went

Abbott Laboratories Q2 FY25: revenue $11.1B (+7% year over year). Net profit $1.8B. Largest cohort Medical Devices $5.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2025
Reported
Jul 30, 2025 10-Q
Sankey diagram of Abbott Laboratories's income statement for Q2 FY25: revenue of $11.1 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$11.1B +7% year over year
Gross profit$6.3B 56% margin
Operating profit$2.1B 18% margin
Net profit$1.8B 16% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
ItemValueShare of revenueYear over year
Revenue 11.1 100% +7%
Medical Devices 5.4 49% +13%
Nutritional Products 2.2 20% +3%
Diagnostic Products 2.2 20% −1%
Established Pharmaceutical… 1.4 13% +7%
Cost of revenue−4.944%
Gross profit6.356% margin+1pp
Research & development−0.77%+0pp
SG&A−3.128%−1pp
Other−0.44%+0pp
Operating profit2.118% margin+2pp
Tax−0.4
Net profit1.816%+3pp
Filing on EDGAR More quarters of ABT

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters